{"slideshow_credits": null, "snippet": "He learned the first lesson of hedge funds: There is no bad press.", "abstract": "Op-Ed article by William D Cohan examines criminal case against Martin Shkreli, who has been charged with securities and wire fraud; notes business press had previously lionized Shkreli for his business strategies concerning prices of pharmaceuticals; suggests Shkreli's case raises question of whether Wall Street can ever be expected to restructure itself to prevent fraud and deception in first place.", "section_name": "Opinion", "print_page": "23", "document_type": "article", "byline": {"person": [{"firstname": "William", "role": "reported", "rank": 1, "organization": ""}], "original": "By WILLIAM D. COHAN"}, "web_url": "http://www.nytimes.com/2015/12/19/opinion/how-martin-shkreli-the-teen-wolf-of-wall-street-thrived.html", "lead_paragraph": "He learned the first lesson of hedge funds: There is no bad press.", "headline": {"print_headline": "The Teen Wolf of Wall Street", "main": "How Martin Shkreli, the Teen Wolf of Wall Street, Thrived", "content_kicker": "Op-Ed Contributor", "kicker": "Op-Ed Contributor"}, "_id": "5674bf2938f0d805d002eb48", "word_count": "898", "multimedia": [{"height": 126, "url": "images/2015/12/19/opinion/19cohanWeb/19cohanWeb-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/12/19/opinion/19cohanWeb/19cohanWeb-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2015/12/19/opinion/19cohanWeb/19cohanWeb-articleLarge.jpg", "legacy": {"xlarge": "images/2015/12/19/opinion/19cohanWeb/19cohanWeb-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/12/19/opinion/19cohanWeb/19cohanWeb-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/12/19/opinion/19cohanWeb/19cohanWeb-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-12-19T00:00:00Z", "source": "The New York Times", "news_desk": "OpEd", "keywords": [{"name": "persons", "value": "Shkreli, Martin (1983- )", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Securities and Commodities Violations", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Banking and Financial Institutions", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Hedge Funds", "is_major": "N", "rank": "4"}, {"name": "organizations", "value": "MSMB Capital Management LLC", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "Retrophin Inc", "is_major": "N", "rank": "6"}, {"name": "organizations", "value": "Turing Pharmaceuticals AG", "is_major": "N", "rank": "7"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "8"}], "blog": [], "subsection_name": null, "type_of_material": "Op-Ed"}